Mohammad Mahdevar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohammad Mahdevar has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
- Atefeh Zamani
Genius Gene, Genetics and Biotechnology Company, Isfahan, Iran
11 shared publications Ensieh Sagheb Sadeghi
Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
8 shared publicationsAtefeh Zamani
4 shared publicationsBehnoosh Nikonezhad
Genius Gene, Genetics and Biotechnology Company, Isfahan, Iran
2 shared publicationsFarnoosh Akbari
Genius Gene, Genetics and Biotechnology Company, Isfahan, Iran
2 shared publicationsMohammad Hadi Masuomi
Genius Gene, Genetics and Biotechnology Company, Isfahan, Iran
2 shared publications
Latest Publications
- 27 August 2026
- Published by Springer Nature in Current Genetic Medicine Reports
- Vol. 14 (1) , 33
Elevated Expression of LINC02257 and LINC00659 in Breast Cancer is Associated with Poor Survival and Immune Cell Infiltration
- 27 August 2026
- Published by Springer Nature in Current Genetic Medicine Reports
- Vol. 14 (1) , 33
Elevated Expression of LINC02257 and LINC00659 in Breast Cancer is Associated with Poor Survival and Immune Cell Infiltration
- Open Access
Cross-Dataset Transcriptomic Analysis Identifies Oxidative Stress–Inflammation Gene Networks Modulated by Nutrigenomic Interventions in Parkinson’s Disease
Inflammation and oxidative stress (OS) are key to Parkinson’s disease (PD). We performed a cross-dataset integrative transcriptomic analysis to identify OS- and inflammation-related hub genes consistently dysregulated in PD and to explore gene–compound relationships using nutrigenomic studies using publicly available datasets. Four GEO datasets (GSE7621, GSE20141, GSE20146, GSE49036) were analysed to identify differentially expressed genes (DEGs), which were intersected with GeneCards OS–inflammation gene sets. Functional enrichment analyses, including gene ontology (GO), pathway over-representation analysis (ORA), and protein-protein interaction (PPI) analysis, were used to identify key pathways and hub genes. Gene–food bioactive compound (FBC) association was explored by integrating PD signatures with nutrigenomic profiles from NutriGenomeDB. We identified 183 DEGs in PD, enriched in synaptic, dopaminergic, OS, and inflammatory pathways. Intersection analysis yielded 26 OS-inflammation-related genes and 10 central regulators, including TH, DDC, SNCA, LRRK2, HSPB1, and HSPA1B. Integration with nutrigenomic datasets revealed opposing-direction transcriptional patterns, with several FBC-associated signatures showing lower expression of stress-related genes and higher expression of dopaminergic markers such as TH, GCH1, and DDC. Overall, this integrative analysis highlights OS–inflammation gene networks in PD and identifies candidate diet–gene associations that warrant further experimental and clinical validation.
Open AccessCross-Dataset Transcriptomic Analysis Identifies Oxidative Stress–Inflammation Gene Networks Modulated by Nutrigenomic Interventions in Parkinson’s Disease
Inflammation and oxidative stress (OS) are key to Parkinson’s disease (PD). We performed a cross-dataset integrative transcriptomic analysis to identify OS- and inflammation-related hub genes consistently dysregulated in PD and to explore gene–compound relationships using nutrigenomic studies using publicly available datasets. Four GEO datasets (GSE7621, GSE20141, GSE20146, GSE49036) were analysed to identify differentially expressed genes (DEGs), which were intersected with GeneCards OS–inflammation gene sets. Functional enrichment analyses, including gene ontology (GO), pathway over-representation analysis (ORA), and protein-protein interaction (PPI) analysis, were used to identify key pathways and hub genes. Gene–food bioactive compound (FBC) association was explored by integrating PD signatures with nutrigenomic profiles from NutriGenomeDB. We identified 183 DEGs in PD, enriched in synaptic, dopaminergic, OS, and inflammatory pathways. Intersection analysis yielded 26 OS-inflammation-related genes and 10 central regulators, including TH, DDC, SNCA, LRRK2, HSPB1, and HSPA1B. Integration with nutrigenomic datasets revealed opposing-direction transcriptional patterns, with several FBC-associated signatures showing lower expression of stress-related genes and higher expression of dopaminergic markers such as TH, GCH1, and DDC. Overall, this integrative analysis highlights OS–inflammation gene networks in PD and identifies candidate diet–gene associations that warrant further experimental and clinical validation.
- Open Access
- 20 February 2026
- Published by Springer Nature in BMC Microbiology
- Vol. 26 (1)
ZnO@Carvacrol nanoparticles effectively suppress biofilm and quorum-sensing mechanisms in MDR Acinetobacter baumannii
Multidrug-resistant (MDR) Acinetobacter baumannii (A. baumannii) is a serious public health concern. This is mainly due to its strong biofilm formation and
- 20 February 2026
- Published by Springer Nature in BMC Microbiology
- Vol. 26 (1)
Open AccessZnO@Carvacrol nanoparticles effectively suppress biofilm and quorum-sensing mechanisms in MDR Acinetobacter baumannii
Multidrug-resistant (MDR) Acinetobacter baumannii (A. baumannii) is a serious public health concern. This is mainly due to its strong biofilm formation and
- Open Access
- 30 December 2025
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Silencing TMEM105 suppresses gastric cancer cell growth and migration via proliferation-associated pathways
Numerous studies in the field of cancer indicate that long non-coding RNAs (lncRNAs) play a significant role in the development and malignancy of various c
- 30 December 2025
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessSilencing TMEM105 suppresses gastric cancer cell growth and migration via proliferation-associated pathways
Numerous studies in the field of cancer indicate that long non-coding RNAs (lncRNAs) play a significant role in the development and malignancy of various c
- 5 December 2025
- Published by Springer Nature in Biochemical Genetics
- Vol. 64 (4) , 5526-5540
Candidate Prognostic LncRNAs Including C2orf49-DT, CAPN10-DT, LOC105371795 as Potential Biomarkers for Colorectal Cancer
Long non-coding RNAs (lncRNAs) have regulatory functions and are linked to various disorders, including cancer. In this study, we investigated signature lncRNAs that may be associated with the pathogenesis of colorectal cancer (CRC) and could serve as diagnostic and prognostic biomarkers. The relationship between lncRNA expression and patient mortality rates was identified using data from The Cancer Genome Atlas. Next, linear models determined the differential expression of lncRNAs in cancer and healthy samples. The association of lncRNA expression with patient prognosis was examined using a Cox regression test, and the risk model was constructed using a subset of lncRNAs. The co-expression network was analyzed to identify the pathways associated with candidate lncRNAs. The expression levels of specific lncRNAs were examined in 35 tumor samples from the Iranian Tumor Bank to validate the in-silico analyses. RNAs were extracted using TRIzol, and their quality was assessed. The qRT-PCR method determined candidate gene expression levels after cDNA synthesis. Our findings showed that C2orf49-DT, CAPN10-DT, and LOC105371795 levels were higher in CRC samples and linked to patients with poor prognoses. The co-expression network data demonstrated that the examined lncRNAs were connected to crucial genes involved in cell proliferation, like E2F3. The RT-qPCR results showed a significant increase in C2orf49-DT, CAPN10-DT, and LOC105371795 compared to healthy tissue samples. We found a significant correlation between the levels of the mentioned lncRNAs and E2F3 expression in the ex vivo data. Our findings suggest that elevated levels of C2orf49-DT, CAPN10-DT, and LOC105371795 may be associated with increased mortality rates in CRC patients. These non-coding RNAs are associated with pathways that promote cell proliferation and are proposed as potential biomarkers for diagnosing and predicting CRC.
- 5 December 2025
- Published by Springer Nature in Biochemical Genetics
- Vol. 64 (4) , 5526-5540
Candidate Prognostic LncRNAs Including C2orf49-DT, CAPN10-DT, LOC105371795 as Potential Biomarkers for Colorectal Cancer
Long non-coding RNAs (lncRNAs) have regulatory functions and are linked to various disorders, including cancer. In this study, we investigated signature lncRNAs that may be associated with the pathogenesis of colorectal cancer (CRC) and could serve as diagnostic and prognostic biomarkers. The relationship between lncRNA expression and patient mortality rates was identified using data from The Cancer Genome Atlas. Next, linear models determined the differential expression of lncRNAs in cancer and healthy samples. The association of lncRNA expression with patient prognosis was examined using a Cox regression test, and the risk model was constructed using a subset of lncRNAs. The co-expression network was analyzed to identify the pathways associated with candidate lncRNAs. The expression levels of specific lncRNAs were examined in 35 tumor samples from the Iranian Tumor Bank to validate the in-silico analyses. RNAs were extracted using TRIzol, and their quality was assessed. The qRT-PCR method determined candidate gene expression levels after cDNA synthesis. Our findings showed that C2orf49-DT, CAPN10-DT, and LOC105371795 levels were higher in CRC samples and linked to patients with poor prognoses. The co-expression network data demonstrated that the examined lncRNAs were connected to crucial genes involved in cell proliferation, like E2F3. The RT-qPCR results showed a significant increase in C2orf49-DT, CAPN10-DT, and LOC105371795 compared to healthy tissue samples. We found a significant correlation between the levels of the mentioned lncRNAs and E2F3 expression in the ex vivo data. Our findings suggest that elevated levels of C2orf49-DT, CAPN10-DT, and LOC105371795 may be associated with increased mortality rates in CRC patients. These non-coding RNAs are associated with pathways that promote cell proliferation and are proposed as potential biomarkers for diagnosing and predicting CRC.
- Open Access
- 6 June 2025
- Published by Springer Nature in Cancer Cell International
- Vol. 25 (1) , 1-14
Insights into the E2F target genes in breast cancer: associations of pathway genes with prognosis and immune cell filtration based on in silico and ex vivo analyses
E2F transcription factors are crucial in various biological processes, including cell proliferation, differentiation, and apoptosis. However, the exact role of E2F target genes in breast cancer (BC), as well as their influence on survival and immune response, remains poorly understood. To investigate the differential expression of E2F target genes and their relationship with patient prognosis and immune cell infiltration, transcriptomic data from the Cancer Genome Atlas database were analyzed. A risk model was developed to identify genes associated with survival. BC samples were clustered into high-expression (C1) and low-expression (C2) groups of E2F target genes. The correlation between gene expression and factors such as survival, immune cell infiltration (CD4 + and CD8 + T cells), and immune checkpoint inhibitors (PD-L1 and PD-L2) was analyzed. We analyzed the link between clusters and clinical characteristics using the chi-squared test. For further investigation, single-cell data from GSE243526 were utilized. For validation, the expression levels of JPT1 and TBRG4 were assessed using RT-qPCR in clinical samples. Genes targeting E2F, such as AURKB, JPT1, TBRG4, and KIF4A, showed increased expression linked to poor patient prognosis, regardless of clinical features. Kaplan-Meier survival analysis revealed that elevated expression of these genes correlated significantly with decreased survival rates and heightened mortality risk. Single-cell data confirmed that candidate genes exhibited higher expression in tumor-associated epithelial cells than healthy ones. Furthermore, samples from group C1 exhibited a lower survival rate than C2. Immune cell infiltration analysis determined that high expression of E2F target genes in the C1 subgroup was associated with diminished T cell infiltration and increased PD-L1 and PD-L2 expression. A strong and significant association was also identified between triple-negative breast cancer and the C1 cluster. RT-qPCR validation confirmed a significant elevation of JPT1 and TBRG4 expression levels relative to adjacent healthy tissues in BC. These findings suggest that E2F target genes, including JPT1 and TBRG4, may act as prognostic biomarkers and contribute to immune evasion in BC. E2F target genes can also offer good potential for classifying and treating patients.
- 6 June 2025
- Published by Springer Nature in Cancer Cell International
- Vol. 25 (1) , 1-14
Open AccessInsights into the E2F target genes in breast cancer: associations of pathway genes with prognosis and immune cell filtration based on in silico and ex vivo analyses
E2F transcription factors are crucial in various biological processes, including cell proliferation, differentiation, and apoptosis. However, the exact role of E2F target genes in breast cancer (BC), as well as their influence on survival and immune response, remains poorly understood. To investigate the differential expression of E2F target genes and their relationship with patient prognosis and immune cell infiltration, transcriptomic data from the Cancer Genome Atlas database were analyzed. A risk model was developed to identify genes associated with survival. BC samples were clustered into high-expression (C1) and low-expression (C2) groups of E2F target genes. The correlation between gene expression and factors such as survival, immune cell infiltration (CD4 + and CD8 + T cells), and immune checkpoint inhibitors (PD-L1 and PD-L2) was analyzed. We analyzed the link between clusters and clinical characteristics using the chi-squared test. For further investigation, single-cell data from GSE243526 were utilized. For validation, the expression levels of JPT1 and TBRG4 were assessed using RT-qPCR in clinical samples. Genes targeting E2F, such as AURKB, JPT1, TBRG4, and KIF4A, showed increased expression linked to poor patient prognosis, regardless of clinical features. Kaplan-Meier survival analysis revealed that elevated expression of these genes correlated significantly with decreased survival rates and heightened mortality risk. Single-cell data confirmed that candidate genes exhibited higher expression in tumor-associated epithelial cells than healthy ones. Furthermore, samples from group C1 exhibited a lower survival rate than C2. Immune cell infiltration analysis determined that high expression of E2F target genes in the C1 subgroup was associated with diminished T cell infiltration and increased PD-L1 and PD-L2 expression. A strong and significant association was also identified between triple-negative breast cancer and the C1 cluster. RT-qPCR validation confirmed a significant elevation of JPT1 and TBRG4 expression levels relative to adjacent healthy tissues in BC. These findings suggest that E2F target genes, including JPT1 and TBRG4, may act as prognostic biomarkers and contribute to immune evasion in BC. E2F target genes can also offer good potential for classifying and treating patients.